• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

4 More States Propose Psychedelic Legalization and Research

Microdose NewsDesk by Microdose NewsDesk
January 31, 2023
in Law & Politics
Reading Time: 3 mins read
A A

2023 has started off as a good year for psychedelic decriminalization.

The year started with Oregon implementing its legalized psilocybin therapy programs, and a few days later, the state of New York announced a bill to legalize some psychedelics for adults 21 and older.

Continuing the trend, we have several other states introducing psychedelic decriminalization measures.

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

New Hampshire

New Hampshire Republicans are getting into the psychedelic reform movement. A new bill from Rep. Kevin Verville (R) would legalize the possession and use of psychedelics by adults 21 and older.

Continue on your trip...

Psylutions and the DEA

US Congress Adds Psychedelics Studies to Defense Bill

Enveric Granted US Patent for Psilocybin Derivatives

The legislation, HB 328-FN, proposes that “possession or use of a hallucinogenic drug by a person 21 years of age or older shall not be an offense.”

The bill has been sent to the House Criminal Justice and Public Safety Committee for review.

 

 

 

Missouri

Another Republican, this time in Missouri, has filed a bill to provide therapeutic access to psilocybin for people with serious mental health conditions.

The proposed bill, HB 969, would allow psilocybin therapy for qualifying patients in need. Rep. Tony Lovasco (R) introduced the bill which would provide patients access to psilocybin for the treatment of PTSD, depression, terminal illness, or other conditions (if approved by regulators).

[bsa_pro_ad_space id=2]
ADVERTISEMENT

The bill does not legalize psilocybin, instead providing legal protections for patients, doctors, caregivers and professionals.

 

 

Washington State

Senators in Washington State have come together in a bipartisan group to introduce a bill

Direct Lasix Purchase

that would provide psychedelic decriminalization services for adults.

The “Psilocybin Services Wellness and Opportunity Act” was filed with 20 cosponsors from both pirates, proposing to legalize and regulate psilocybin for adults 21 and older.

The new bill would: “facilitate the establishment of safe, legal, and affordable psilocybin service centers to provide citizens of Washington who are at least 21 years of age with opportunities for supported psilocybin experiences for wellness and personal growth..”

“…reduce the prevalence of behavioral health disorders among adults in this state by providing for supported adult use of psilocybin under the supervision of a trained and licensed psilocybin service facilitator,” it says.

The bill already has 20 Senators on board.

 

The Psilocybin Wellness and Opportunity Act is once again 🔔 LIVE! With🚨*20*🚨 co-sponsors! This is huge.
Can we get 1k comments in support of the bill? 📢https://t.co/6bnsJITwDc
Like and share, don't let the Washington State gov ignore this! #waleg

— Psychedelic Medicine Alliance WA (@pma_wa) January 11, 2023

 

Arizona

In Arizona, a bipartisan group of lawmakers filed a bill promoting psilocybin research.

The legislation, HB 2486, was proposed by Reps. Jennifer Longdon (D), Kevin Payne (R), Sen. T. J. Shope (R), and Stacey Travers (D) would allocate $30 million for psilocybin research and establish a psilocybin research advisory council. The aim is to study how psilocybin can help on over a dozen different conditions like anxiety, post-traumatic stress disorder, depression, and substance abuse.

The research and related grants could also be used for FDA clinical trials.

 

 

Tags: Decriminalizationpsilocybin
Microdose NewsDesk

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Next Post
Origin Signs Letter of Intent to Acquire Safe Supply Streaming

Origin Signs Letter of Intent to Acquire Safe Supply Streaming

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.